Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C
dc.contributor.author | Fontana, Robert John | en_US |
dc.contributor.author | Moyer, Cheryl A. | en_US |
dc.contributor.author | Sonnad, Seema S. | en_US |
dc.contributor.author | Lok, Anna Suk-Fong | en_US |
dc.contributor.author | Sneed-Pee, Naomi | en_US |
dc.contributor.author | Walsh, John | en_US |
dc.contributor.author | Klein, Steven | en_US |
dc.contributor.author | Webster, Steven | en_US |
dc.date.accessioned | 2010-06-01T19:37:33Z | |
dc.date.available | 2010-06-01T19:37:33Z | |
dc.date.issued | 2001-01 | en_US |
dc.identifier.citation | Fontana, Robert J . ; Moyer, Cheryl A . ; Sonnad, Seema; Lok, Anna S.F . ; Sneed-Pee, Naomi; Walsh, John; Klein, Steven; Webster, Steven (2001). "Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C." The American Journal of Gastroenterology 96(1): 170-178. <http://hdl.handle.net/2027.42/72761> | en_US |
dc.identifier.issn | 0002-9270 | en_US |
dc.identifier.issn | 1572-0241 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/72761 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=11197249&dopt=citation | en_US |
dc.description.abstract | Patients with chronic hepatitis C (HCV) consistently report a reduction in multiple domains of health-related quality of life (HRQOL) that does not correlate with liver disease severity. This may in part be due to the use of insensitive HRQOL instruments or extrahepatic factors that independently influence HRQOL. We hypothesized that a past history of substance abuse or active medical and psychiatric comorbidities would correlate with HRQOL scores. Methods In 107 patients who had failed previous interferon therapy, HRQOL was measured by using the modified SF-36, a disease-specific instrument, and the Health Utilities Index (HUI) Mark III, a generic instrument. Results Multiple SF-36 subscale and summary scores as well as the HUI Mark III attributes of emotion and pain were significantly reduced in the study population compared with healthy controls ( p < 0.001). Serum alanine aminotransferase and HCV RNA levels, HCV genotype, liver histology, and HCV risk factors as well as demographic variables did not correlate with modified SF-36 and HUI scores. In addition, a history of alcohol abuse or dependency and intravenous drug use or dependency, identified in 52 and 51% of participants, respectively, did not correlate with HRQOL scores. However, the presence of one or more active medical comorbidities, defined as a chronic medical condition requiring treatment and monitoring, was significantly associated with both the modified SF-36 scores and HUI attribute deficits ( p < 0.001). In particular, painful medical comorbidities or depressed mood requiring treatment were significantly associated with modified SF-36 scores and with HUI attribute deficits and utility scores ( p < 0.001). Conclusions Active medical and psychiatric comorbidities may account for some of the reduction and variability in HRQOL scores in patients with chronic HCV who have failed previous interferon therapy. Future studies that control for the presence of active comorbidities in large groups of treatment naÏve patients with varying severity of chronic HCV are needed to confirm these findings. | en_US |
dc.format.extent | 287825 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/octet-stream | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.rights | 2001 by Am. Coll. of Gastroenterology | en_US |
dc.title | Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationum | Consortium for Health Outcomes Innovation and Cost-Effectiveness Studies (CHOICES), Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationum | Department of Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationum | Huron Gastroenterology Associates, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationum | Botsford Hospital, Farmington Hills, Michigan, USA | en_US |
dc.contributor.affiliationum | Muskegon General Hospital, Muskegon, Michigan, USA | en_US |
dc.identifier.pmid | 11197249 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/72761/1/j.1572-0241.2001.03473.x.pdf | |
dc.identifier.doi | 10.1111/j.1572-0241.2001.03473.x | en_US |
dc.identifier.source | The American Journal of Gastroenterology | en_US |
dc.identifier.citedreference | Seeff L.B. Natural history of hepatitis C. Hepatology 1997; 26 ( suppl ): 21S – 28S. | en_US |
dc.identifier.citedreference | Alter M.J., Kruszon-Moran D., Nainan O.V., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556 – 562. | en_US |
dc.identifier.citedreference | 3. National Institutes of Health Consensus Development Conference Panel Statement Management of hepatitis C. Hepatology 1997; 26 ( suppl ): 2S – 10S. | en_US |
dc.identifier.citedreference | Villano S.A., Vlahove D., Nelson K.E., et al. Persistence of viremia and the importance of long term follow-up after acute hepatitis C infection. Hepatology 1999; 29: 908 – 914. | en_US |
dc.identifier.citedreference | Hoofnagle J.H. Hepatitis C. The clinical spectrum of disease. Hepatology 1997; 26 ( suppl ): 15S – 20S. | en_US |
dc.identifier.citedreference | Barkhuizen A., Rosen H.R., Wolf S., et al. Musculoskeletal pain and fatigue are associated with chronic hepatitis C. Am J Gastroenterol 1999; 94: 1355 – 1360. | en_US |
dc.identifier.citedreference | Koff R.S., Dienstag J.L. Extrahepatic manifestations of hepatitis C and the association with alcoholic liver disease. Semin Liver Dis 1995; 15: 101 – 109. | en_US |
dc.identifier.citedreference | Davis G.L., Balart L.A., Schiff E.R., et al. Assessing HRQOL in chronic hepatitis C using the SIP. Clin Ther 1994; 16: 334 – 343. | en_US |
dc.identifier.citedreference | Carithers R.L., Sugano D., Bayliss M. Health assessment for chronic HCV. Dig Dis Sci 1996; 41 ( suppl ): 75S – 80S. | en_US |
dc.identifier.citedreference | Foster G.R., Goldin R.D., Thomas H.C. Chronic Hepatitis C virus infection causes a significant reduction in HRQOL in the absence of cirrhosis. Hepatology 1998; 27: 209 – 212. | en_US |
dc.identifier.citedreference | Bayliss M.S., Gandek B., Bungay K.M., et al. A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic Hepatitis C. Qual Life Res 1998; 7: 39 – 55. | en_US |
dc.identifier.citedreference | Consensus IFN Study Group Bonkovsky H.L., Wooley J.M., the Consensus IFN Study Group. Reduction of HRQOL in chronic hepatitis C and improvement with IFN therapy. Hepatology 1999; 29: 264 – 270. | en_US |
dc.identifier.citedreference | Ware J.E., Bayliss M.S., Mannocchia M., International Hepatitis Interventional Therapy Group. Health-related quality of life in chronic hepatitis C: Impact of disease and treatment response. Hepatology 1999; 30: 550 – 555. | en_US |
dc.identifier.citedreference | Neary M.P., Cort S., Bayliss M.S., et al. Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients. Semin Liv Dis 1999; 19 ( suppl 1 ): 77S – 85S. | en_US |
dc.identifier.citedreference | Cannon D.S., Bell W.E., Fowler D.R., et al. MMPI differences between alcoholics, and drug abusers. Psychol Assess 1990; 3: 51 – 55. | en_US |
dc.identifier.citedreference | Hesselbroack M.N., Meyer R.E., Keener J.J. Psychopathology in hospitalized alcoholics. Arch Gen Psychiatry 1985; 42: 1050 – 1055. | en_US |
dc.identifier.citedreference | Kendall J., Sherman M., Bigelow G. Psychiatric symptoms in polysubstance abusers: Relationship to race, age, sex and age. Addict Behav 1995; 20: 685 – 690. | en_US |
dc.identifier.citedreference | Lipsitz J., Williams J., Rabkin J., et al. Psychopathology in male and female intravenous drug users with and without HIV infection. Am J Psychiatry 1994; 151: 1662 – 1668. | en_US |
dc.identifier.citedreference | Stewart A.L., Greenfield S., Hays R.D., et al. Functional status and well-being of patients with chronic conditions. JAMA 1989; 262: 907 – 913. | en_US |
dc.identifier.citedreference | Ware J.E., Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). Med Care 1992; 30: 473 – 483. | en_US |
dc.identifier.citedreference | Bayliss M.S. Methods in outcomes research in hepatology: Definitions and domains of quality of life. Hepatology 1999; 29 ( suppl 1 ): 7S – 8S. | en_US |
dc.identifier.citedreference | Feeny D., Furlong W., Boyle M., et al. Multi-attribute health status classification systems. Pharmacoeconomics 1995; 7: 490 – 502. | en_US |
dc.identifier.citedreference | Kantz M.E., Harris W.J., Levitsky K., et al. Methods for assessing condition-specific and generic functional status outcomes after total knee replacement. Med Care 1992; 30: 240 – 252. | en_US |
dc.identifier.citedreference | Alter M.J. Epidemiology of Hepatitis C. Hepatology 1997; 26 ( suppl ): 62S – 65S. | en_US |
dc.identifier.citedreference | Conry-Cantilena C., VanRaden M., Gibble J., et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C infection. N Engl J Med 1996; 334: 1691 – 1696. | en_US |
dc.identifier.citedreference | Skinner H.A., Sheu W.J. Reliability of alcohol use indices: Lifetime drinking history and MAST. J Stud Alcohol 1982; 43: 1157 – 1170. | en_US |
dc.identifier.citedreference | Ewing J.A. Detecting alcoholism, the CAGE questionnaire. JAMA 1984; 252: 1905 – 1907. | en_US |
dc.identifier.citedreference | Gavin D., Ross H., Skinner H. Diagnostic accuracy of the drug abuse screening test. Br J Addict 1989; 84: 301 – 305. | en_US |
dc.identifier.citedreference | Pockros P.J., Bain V.G., Hunter E.B., et al. A comparison of reverse transcription-polymerase chain reaction and branched-chain DNA assays for hepatitis C virus RNA in patients receiving Interferon treatment. J Viral Hepatitis 1999; 6: 145 – 150. | en_US |
dc.identifier.citedreference | Stuvyer L., Rossau R., Wyseur A., et al. Typing of hepatitis C virus isolates and characterization of new genotypes. J Gen Virol 1993; 74: 1093 – 1102. | en_US |
dc.identifier.citedreference | Moyer C.A., Fendrick A.M. Measuring health-related quality of life in patients with upper gastrointestinal disease. Dig Dis 1998; 16: 315 – 324. | en_US |
dc.identifier.citedreference | Ware J.E., Sherbourne C. The MOS 36-item short-form health survey. Conceptual framework and item selection. Med Care 1992; 30: 473 – 483. | en_US |
dc.identifier.citedreference | Ware J.E., Kosinski M., Bayliss M.S., et al. Comparison of methods for the scoring and statitistical analysis of the SF-36 health profiles and summary measures: Summary of results from the Medical Outcomes Study. Med Care 1995; 33 ( suppl 4 ): AS264 – AS279. | en_US |
dc.identifier.citedreference | 34. Statistics Canada General Social Survey Analysis Series. Health Status of Canada. Catalogue 11-612E No 8, Ottawa, Canada, 1991. | en_US |
dc.identifier.citedreference | Mahaney K., Tedeschi V., Maertens G., et al. Genotypic analysis of hepatitis C virus in American patients. Hepatology 1994; 20: 1405 – 1411. | en_US |
dc.identifier.citedreference | Schachat A.P. Common problems associated with impaired vision. In: Barker L.R., Burton J.R., Zieve P.D., eds. Principles of ambulatory medicine, 4th ed. Philadelphia: Williams & Wilkins, 1995: 1415 – 1422. | en_US |
dc.identifier.citedreference | Grant I., Adams K.M., Neuropsychological assessment of neuropsychiatric disorders. New York: Oxford Press, 1996: 200 – 217. | en_US |
dc.identifier.citedreference | Boyle M.H., Fulong W., Feeny D., et al. Reliability of the Health Utilities Index-Mark III used in the 1991 cycle 6 Canadian General Social Survey Health Questionnaire. Qual Life Res 1995; 4: 249 – 257. | en_US |
dc.identifier.citedreference | McHorney C.A., Ware J.E., Faczek A.E. The MOS 36-Item Short from Health Survey (SF-36): Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31: 247 – 263. | en_US |
dc.identifier.citedreference | Haber M.M., West A.B., Haber A.D., et al. Relationship of aminotransferases to liver histological status in chronic hepatitis C. Am J Gastroenterol 1995; 90: 1250 – 1257. | en_US |
dc.identifier.citedreference | McCormick S.E., Goodman Z.D., Maydonovitch C.L., et al. Evaluation of liver histology, ALT elevation, and HCV RNA titer in patients with chronic hepatitis C. Am J Gastroenterol 1996; 91: 1516 – 1522. | en_US |
dc.identifier.citedreference | Rounsaville B.J., Weissman M.M., Kleber H., et al. Heterogeneity of psychiatric diagnosis in treated opiate addicts. Arch Gen Psychiatry 1982; 39: 161 – 166. | en_US |
dc.identifier.citedreference | Dinwiddie S.H., Reich T., Clininger R.C. Psychiatric comorbidity and suicidality among intravenous drug users. J Clin Psychiatry 1992; 53: 364 – 369. | en_US |
dc.identifier.citedreference | Xuan J., Kirchdoerfer L.J., Boyer J.G., et al. Effects of comorbidity on health-related quality of life scores: An analysis of clinical trial data. Clin Ther 1999; 2192: 383 – 403. | en_US |
dc.identifier.citedreference | Pauly M.P., Ready J., Szpakowski J., et al. Increased cost of care in hepatitis C is due to comorbid medical conditions until the development of decompensated cirrhosis. Hepatology 1999; 30: A167 ( abstract ) | en_US |
dc.identifier.citedreference | Nielsen A.R., Williams T.A. Depression in ambulatory medical patients. Arch Gen Psychiatry 1980; 37: 999 – 1004. | en_US |
dc.identifier.citedreference | Mulrow C.D., Williams J.W., Gerety M.B., et al. Case-finding instruments for depression in primary care settings. Ann Intern Med 1995; 122: 913 – 921. | en_US |
dc.identifier.citedreference | Raft D., Davidson J., Toomey T.C., et al. Inpatient and outpatient patterns of psychotropic drug prescribing by nonpsychiatric physicians. Am J Psychiatry 1975; 132: 1309 – 1312. | en_US |
dc.identifier.citedreference | Hunt C.M., Dominitz J.A., Bute B.P., et al. Effect of interferon—a treatment of chronic hepatitis C on health related quality of life. Dig Dis Sci 1997; 42: 2482 – 2486. | en_US |
dc.identifier.citedreference | Johnson M.E., Fisher D.G., Fenaughty A., et al. Hepatitis C virus, and depression in drug users. Am J Gastroenterol 1998; 93: 785 – 789. | en_US |
dc.identifier.citedreference | Koff R.S. Impaired health-related quality of life in chronic hepaitits C: The how but not the why. Hepatology 1999; 29: 177 – 279. | en_US |
dc.identifier.citedreference | Rodger A.J., Jolley D., Thompson S.C., et al. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology 1999; 30: 1299 – 1301. | en_US |
dc.identifier.citedreference | Karlsen K.H., Larsen J.P., Tandberg E., et al. Influence of clinical and demographic variables on quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999; 66: 431 – 435. | en_US |
dc.identifier.citedreference | Revicki D.A., Leidy N.K., Brenna-Diemer F., et al. Integrating patient preferences into health outcomes assessment. The multi-attribute asthma symptom utility index. Chest 1998; 114: 998 – 1007. | en_US |
dc.identifier.citedreference | Owens D.K., Cardinalli A.B., Nease R.F. Physician's assessments of the utility of health states associated with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. Qual Life Res 1997; 6: 77 – 86. | en_US |
dc.identifier.citedreference | Mathias S.D., Bates M.M., Pasta D.J., et al. Use of the health utilities index with stroke patients and their caregivers. Stroke 1997; 28: 1888 – 1894. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.